MTFMT

Across TCGA pan-cancer cohorts, MTFMT mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MTFMT’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MTFMT mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MTFMT is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where MTFMT tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTFMT mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.854	<.001	12	view →
LUAD	All	All	+0.175	.003	6	view →
HNSC	Male	II,III,IV	−0.161	.005	5	view →
LSCC	All	All	+0.155	.006	5	view →
PDAC	Male	II,III,IV	+0.633	.008	3	view →
COAD	Male	III,IV	−0.327	.026	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MTFMT–CCRCC

Open the CCRCC breakdown →